ClinicalTrials.gg
CompletedNCT00171249Updated Jul 22, 2021Results posted

An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia

A Phase 2 interventional study of STI571 400 mg and STI571 600 mg in Philadelphia Positive Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 12 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-22.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 6 years 1 month after the study started (first participant enrolled Aug 1999, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
293
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing imatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 3 open to participants now, 4 under way, 2 of them phase 3. imatinib · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Enrollment
8th of 27
293 · median 70
Started
1999
with 1 other
Phase 2
16 of 29
2 open now
Registered
12th of 29
by date
Lead sponsor
4 of 29
Novartis Pharmaceuticals

Among the 29 studies testing imatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 8th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 1999, is one of 16 in phase 2, and was the 12th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

3 of the 29 studies testing imatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About imatinib

imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing imatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

The objectives of Part 1 of the study were:

  • To determine the rate of hematologic response (HR) lasting ≥4 weeks in participants with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the accelerated phase (AP).
  • To evaluate duration of HR, overall survival, cytogenetic response (CyR), time to blast crisis in CML participants in the AP, improvement of symptomatic parameters, tolerability and safety of STI571 treatment.

The objective of the extension (Part 2) was:

-To enable participants to have access to study drug and continue study treatment and to decrease data collection to include only overall survival and serious adverse events.

03

Conditions studied

  • Philadelphia Positive Chronic Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia

Keywords

  • Chronic Myelogenous Leukemia
  • CML
  • Philadelphia Chromosome
  • Accelerated phase
  • Acute Myelogenous Leukemia
  • AML
  • Acute Lymphoblastic Leukemia
  • ALL
  • Imatinib mesylate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants, aged ≥18 years, with a confirmed diagnosis of Ph+ leukemia of one of the following types:

    • Accelerated phase chronic myeloid/myelogenous leukemia (CML).
    • Acute lymphoid/lymphoblastic leukemia (ALL) or acute myeloid/myelogenous leukemia (AML) in first or subsequent relapse after either standard chemotherapy, or allogeneic bone marrow transplantation, or high-dose treatment with peripheral blood stem cell support, or
    • ALL or AML to standard chemotherapy (no complete remission achieved after two courses of conventional induction chemotherapy).
    • Lymphoid blastic phase of CML in first or subsequent relapse or refractory to standard chemotherapy.
  • With serum serum glutamate oxaloacetate transaminase () and serum glutamate pyruvate transaminase (alanine aminotransferase) not more than 3 x (ULN) (or not more than 5xULN if clinically suspected leukemic involvement of the liver), serum creatinine concentration not more than 2xULN, and total serum level not more than 3xULN (bilirubin limit was 1.5xULN before protocol amendment 1)

Exclusion criteria

Exclusion Criteria:

  • Participants who had an (ECOG) performance status score ≥3.
  • Participants with known leukemic involvement of the central nervous system (CNS).
  • Participants who had received treatment with any of the following agents: interferon-alpha within 48 hours, hydroxyurea within 24 hours, homoharringtonine within 14 days, low-dose, moderate dose or high dose cytosine arabinoside within 7, 14 or 28 days respectively, 6-mercaptopurine, vinca alkaloids or within 7 days, anthracyclines, mitoxantrone, etoposide, methotrexate, cyclophosphamide within 21 days, or busulfan within 6 weeks.
  • Participants who had undergone hematopoietic stem cell transplantation within six weeks of Day 1, or who had not achieved full hematopoietic recovery following the transplant.
  • Participants with grade 3/4 cardiac disease or any serious, concomitant, medical condition.
  • Participants with a history of non-compliance to medical regimens or who were considered potentially unreliable.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
293 participants (actual)

Study arms

  • Experimental
    Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 400 mg

    Participants with accelerated phase chronic myeloid/myelogenous leukemia received STI571 400 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.

    Drug: STI571 400 mg

  • Experimental
    Lymphoid Blast Crisis 400 mg

    Participants with lymphoid blast crisis received STI571 400 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.

    Drug: STI571 400 mg

  • Experimental
    Acute Lymphoblastic Leukemia 400 mg

    Participants with acute lymphoblastic leukemia received STI571 400 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.

    Drug: STI571 400 mg

  • Experimental
    Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 600 mg

    Participants with accelerated phase chronic myeloid/myelogenous leukemia received STI571 600 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.

    Drug: STI571 600 mg

  • Experimental
    Lymphoid Blast Crisis 600 mg

    Participants with lymphoid blast crisis received STI571 600 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.

    Drug: STI571 600 mg

  • Experimental
    Acute Lymphoblastic Leukemia 600 mg

    Participants with acute lymphoblastic leukemia received STI571 600 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.

    Drug: STI571 600 mg

  • Experimental
    Acute Myeloid/Myelogenous Leukemia 600 mg

    Participants with acute myeloid/myelogenous leukemia received STI571 600 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.

    Drug: STI571 600 mg

Interventions

  • STI571 capsules and tablets

    Also known as: Imatinib mesylate, Glivec®, GleevecTM

  • STI571 capsules and tablets

    Also known as: Imatinib mesylate, Glivec®, GleevecTM

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Hematologic Response in Accelerated Phase Chronic Myeloid/Myelogenous Leukemia

    Hematologic response was evaluated from hematology measurements in the peripheral blood (PB) and bone marrow (BM) and assessments of extramedullary leukemic involvement (EMD) at physical examination. Response was defined as complete hematologic remission (CHR), no evidence of leukemia (NEL), or return to chronic phase (RTC).

    Time frame: Up to 3 years after start of treatment

Secondary outcomes

  1. Percentage of Participants With Cytogenetic Response in Accelerated Phase Chronic Myeloid/Myelogenous Leukemia

    Bone marrow (BM) cytogenetic analysis was required at baseline, after 12 weeks (visit 22) and after 24 weeks (visit 28) to evaluate Ph chromosome positivity. In several participants, this was also done after 4 and 8 weeks. Based on the percentage of Philadelphia chromosome positive (Ph+) cells = (positive cells/examined cells)x100, at each BM assessment the cytogenetic response was classified as: Complete, 0% Ph+ cells; Partial, \>0 - 35% Ph+ cells; Minor, \>35 - 65% Ph+ cells; Minimal, \>65 - 95% Ph+ cells; None, \>95% Ph+ cells; Not done: \<20 metaphases were examined and/or response could not be assigned. Cytogenetic response was defined as confirmed complete or partial response. A BM sample was considered as assessable for cytogenetic response only if it contained ≥20 metaphases. However, an assessment of partial response was retained in a sample with \<20 metaphases when it was immediately preceded or followed by a complete or partial response in another sample with ≥20 metaphases.

    Time frame: Up to 3 years after start of treatment

  2. Time to Response in Participants With Accelerated Phase Chronic Myeloid/Myelogenous Leukemia

    Time to response was defined for all participants as the time until first documented response (which was confirmed ≥4 weeks later).

    Time frame: Up to 3 years after start of treatment

  3. Duration of Response in Participants With Accelerated Phase Chronic Myeloid/Myelogenous Leukemia

    Duration of response was defined as the time between first documented response (which was confirmed ≥4 weeks later) and the earliest date of the following: loss of response (when any of the criteria for response were no longer fulfilled); progression to blast crisis (≥30% blasts in peripheral blood or bone marrow, extramedullary involvement other than liver/spleen enlargement); discontinuation due to adverse event, laboratory abnormality, unsatisfactory therapeutic effect or death.

    Time frame: Up to 3 years after start of treatment

  4. Time to Progression to Blast Crisis in Participants With Accelerated Phase Chronic Myeloid/Myelogenous Leukemia

    Progression to blast crisis was defined as ≥30% blasts in peripheral blood or bone marrow or as extramedullary involvement other than liver or spleen enlargement.

    Time frame: Up to 3 years after start of treatment

  5. Overall Survival by Disease

    To evaluate overall survival, all participants were followed after the last dose of study drug every month for the first three months and thereafter every three months until death. Overall survival was calculated for all participants as the time between start of treatment and death due to any reason. The time was censored at the date of last contact for participants who discontinued treatment and were in survival follow-up. For participants without survival follow-up information, the time was censored at last available visit/treatment date.

    Time frame: 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156 months after start of treatment

  6. Overall Survival by Dose in Participants With Accelerated Phase Chronic Myeloid/Myelogenous Leukemia

    To evaluate overall survival, all participants were followed after the last dose of study drug every month for the first three months and thereafter every three months until death. Overall survival was calculated for all participants as the time between start of treatment and death due to any reason. The time was censored at the date of last contact for participants who discontinued treatment and were in survival follow-up. For participants without survival follow-up information, the time was censored at last available visit/treatment date.

    Time frame: 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132 months after start of treatment

07

Results

Posted Jul 22, 2021

Participant flow

Participants took part in this study at 14 investigative sites in France, Germany, Italy, United Kingdom, Switzerland and United States from August 9, 1999 to September 23, 2013.

Participant flow — Overall Study
MilestoneAccelerated Phase Chronic Myeloid/Myelogenous Leukemia 400 mgLymphoid Blast Crisis 400 mgAcute Lymphoblastic Leukemia 400 mgAccelerated Phase Chronic Myeloid/Myelogenous Leukemia 600 mgLymphoid Blast Crisis 600 mgAcute Lymphoblastic Leukemia 600 mgAcute Myeloid/Myelogenous Leukemia 600 mg
Started77551583432
Completed part 15001125260
Completed1006000
Not completed76551523432
Withdrew: Withdrawal by subject2006000
Withdrew: Unsatisfactory therapeutic effect4435703311
Withdrew: Death7104031
Withdrew: Other100043020
Withdrew: No longer requires study drug4003050
Withdrew: Administrative problems1002000
Withdrew: Adverse event31015020
Withdrew: Lost to follow-up5009000

Outcome measures

PrimaryPercentage of Participants With Hematologic Response in Accelerated Phase Chronic Myeloid/Myelogenous Leukemia

Hematologic response was evaluated from hematology measurements in the peripheral blood (PB) and bone marrow (BM) and assessments of extramedullary leukemic involvement (EMD) at physical examination. Response was defined as complete hematologic remission (CHR), no evidence of leukemia (NEL), or return to chronic phase (RTC).

Time frame:
Up to 3 years after start of treatment
Reported as:
Number · percentage of participants
Percentage of Participants With Hematologic Response in Accelerated Phase Chronic Myeloid/Myelogenous Leukemia
percentage of participantsAccelerated Phase Chronic Myeloid/Myelogenous Leukemia 400 mgAccelerated Phase Chronic Myeloid/Myelogenous Leukemia 600 mg
Percentage of Participants With Hematologic Response in Accelerated Phase Chronic Myeloid/Myelogenous Leukemia64.9 (53.2 to 75.5)74.7 (67.2 to 81.3)
SecondaryPercentage of Participants With Cytogenetic Response in Accelerated Phase Chronic Myeloid/Myelogenous Leukemia

Bone marrow (BM) cytogenetic analysis was required at baseline, after 12 weeks (visit 22) and after 24 weeks (visit 28) to evaluate Ph chromosome positivity. In several participants, this was also done after 4 and 8 weeks. Based on the percentage of Philadelphia chromosome positive (Ph+) cells = (positive cells/examined cells)x100, at each BM assessment the cytogenetic response was classified as: Complete, 0% Ph+ cells; Partial, \>0 - 35% Ph+ cells; Minor, \>35 - 65% Ph+ cells; Minimal, \>65 - 95% Ph+ cells; None, \>95% Ph+ cells; Not done: \<20 metaphases were examined and/or response could not be assigned. Cytogenetic response was defined as confirmed complete or partial response. A BM sample was considered as assessable for cytogenetic response only if it contained ≥20 metaphases. However, an assessment of partial response was retained in a sample with \<20 metaphases when it was immediately preceded or followed by a complete or partial response in another sample with ≥20 metaphases.

Time frame:
Up to 3 years after start of treatment
Reported as:
Number · percentage of participants
Percentage of Participants With Cytogenetic Response in Accelerated Phase Chronic Myeloid/Myelogenous Leukemia
percentage of participantsAccelerated Phase Chronic Myeloid/Myelogenous Leukemia 400 mgAccelerated Phase Chronic Myeloid/Myelogenous Leukemia 600 mg
Percentage of Participants With Cytogenetic Response in Accelerated Phase Chronic Myeloid/Myelogenous Leukemia14.3 (7.4 to 24.1)24.7 (18.2 to 32.2)
SecondaryTime to Response in Participants With Accelerated Phase Chronic Myeloid/Myelogenous Leukemia

Time to response was defined for all participants as the time until first documented response (which was confirmed ≥4 weeks later).

Time frame:
Up to 3 years after start of treatment
Reported as:
Median · months
Time to Response in Participants With Accelerated Phase Chronic Myeloid/Myelogenous Leukemia
monthsAccelerated Phase Chronic Myeloid/Myelogenous Leukemia 400 mgAccelerated Phase Chronic Myeloid/Myelogenous Leukemia 600 mg
Hematologic response0.95 (0.95 to 1.1)0.99 (0.99 to 1)
Cytogenetic response2.83 (1.9 to 5.6)2.96 (2.8 to 5.5)
SecondaryDuration of Response in Participants With Accelerated Phase Chronic Myeloid/Myelogenous Leukemia

Duration of response was defined as the time between first documented response (which was confirmed ≥4 weeks later) and the earliest date of the following: loss of response (when any of the criteria for response were no longer fulfilled); progression to blast crisis (≥30% blasts in peripheral blood or bone marrow, extramedullary involvement other than liver/spleen enlargement); discontinuation due to adverse event, laboratory abnormality, unsatisfactory therapeutic effect or death.

Time frame:
Up to 3 years after start of treatment
Reported as:
Median · months
Duration of Response in Participants With Accelerated Phase Chronic Myeloid/Myelogenous Leukemia
monthsAccelerated Phase Chronic Myeloid/Myelogenous Leukemia 400 mgAccelerated Phase Chronic Myeloid/Myelogenous Leukemia 600 mg
Hematologic response16.46 (10.4 to 27.4)28.81 (25.7 to NA)
Cytogenetic response26.28 (6.6 to NA)27.63 (15.9 to NA)
SecondaryTime to Progression to Blast Crisis in Participants With Accelerated Phase Chronic Myeloid/Myelogenous Leukemia

Progression to blast crisis was defined as ≥30% blasts in peripheral blood or bone marrow or as extramedullary involvement other than liver or spleen enlargement.

Time frame:
Up to 3 years after start of treatment
Reported as:
Median · months
Time to Progression to Blast Crisis in Participants With Accelerated Phase Chronic Myeloid/Myelogenous Leukemia
monthsAccelerated Phase Chronic Myeloid/Myelogenous Leukemia 400 mgAccelerated Phase Chronic Myeloid/Myelogenous Leukemia 600 mg
Time to Progression to Blast Crisis in Participants With Accelerated Phase Chronic Myeloid/Myelogenous Leukemia9.95 (6.6 to 14.4)25.13 (18.1 to 29.8)
SecondaryOverall Survival by Disease

To evaluate overall survival, all participants were followed after the last dose of study drug every month for the first three months and thereafter every three months until death. Overall survival was calculated for all participants as the time between start of treatment and death due to any reason. The time was censored at the date of last contact for participants who discontinued treatment and were in survival follow-up. For participants without survival follow-up information, the time was censored at last available visit/treatment date.

Time frame:
12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156 months after start of treatment
Reported as:
Number · percentage of participants
Overall Survival by Disease
percentage of participantsAccelerated Phase Chronic Myeloid/Myelogenous LeukemiaLymphoid Blast CrisisAcute Lymphoid LeukemiaAcute Myeloid/Myelogenous Leukemia
12 months74.4 (68.3 to 79.5)12.5 (0.7 to 42.3)10.4 (3.8 to 20.9)0 (0 to 0)
24 months58.8 (52.2 to 64.8)0 (0 to 0)8.3 (2.7 to 18.2)0 (0 to 0)
36 months48 (41.4 to 54.2)0 (0 to 0)8.3 (2.7 to 18.2)0 (0 to 0)
48 months39.9 (33.5 to 46.2)0 (0 to 0)8.3 (2.7 to 18.2)0 (0 to 0)
60 months32.2 (26.1 to 38.4)0 (0 to 0)8.3 (2.7 to 18.2)0 (0 to 0)
72 months26.3 (20.6 to 32.3)0 (0 to 0)8.3 (2.7 to 18.2)0 (0 to 0)
84 months24.1 (18.6 to 30.1)0 (0 to 0)8.3 (2.7 to 18.2)0 (0 to 0)
96 months21.9 (16.5 to 27.8)0 (0 to 0)5.6 (1.2 to 15.2)0 (0 to 0)
108 months20.6 (15.3 to 26.4)0 (0 to 0)5.6 (1.2 to 15.2)0 (0 to 0)
120 months20.6 (15.3 to 26.4)0 (0 to 0)5.6 (1.2 to 15.2)0 (0 to 0)
132 months18.9 (13.6 to 24.8)0 (0 to 0)5.6 (1.2 to 15.2)0 (0 to 0)
144 months18.9 (13.6 to 24.8)0 (0 to 0)5.6 (1.2 to 15.2)0 (0 to 0)
156 months18.9 (13.6 to 24.8)0 (0 to 0)5.6 (1.2 to 15.2)0 (0 to 0)
SecondaryOverall Survival by Dose in Participants With Accelerated Phase Chronic Myeloid/Myelogenous Leukemia

To evaluate overall survival, all participants were followed after the last dose of study drug every month for the first three months and thereafter every three months until death. Overall survival was calculated for all participants as the time between start of treatment and death due to any reason. The time was censored at the date of last contact for participants who discontinued treatment and were in survival follow-up. For participants without survival follow-up information, the time was censored at last available visit/treatment date.

Time frame:
12, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 132 months after start of treatment
Reported as:
Number · percentage of participants
Overall Survival by Dose in Participants With Accelerated Phase Chronic Myeloid/Myelogenous Leukemia
percentage of participantsAccelerated Phase Chronic Myeloid/Myelogenous Leukemia 400 mgAccelerated Phase Chronic Myeloid/Myelogenous Leukemia 600 mg
12 months64.5 (52.6 to 74.1)79.1 (71.9 to 84.7)
24 months44.3 (32.9 to 55.1)65.7 (57.7 to 72.6)
36 months34.9 (24.4 to 45.7)54.2 (46.0 to 61.6)
48 months28.0 (18.4 to 38.5)45.6 (37.6 to 53.2)
60 months23.7 (14.7 to 33.9)36.2 (28.6 to 43.9)
72 months18.6 (10.5 to 28.5)29.9 (22.6 to 37.5)
84 months15.2 (7.8 to 24.8)28.3 (21.2 to 35.9)
96 months11.8 (5.4 to 21.0)26.6 (19.6 to 34.2)
108 months11.8 (5.4 to 21.0)24.8 (17.9 to 32.3)
120 months11.8 (5.4 to 21.0)24.8 (17.9 to 32.3)
132 months11.8 (5.4 to 21.0)22.3 (15.4 to 29.9)

Adverse events

Collected over Up to approximately 14 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
STI571—20/293 (6.8%)—
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventSTI571
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/293
DeathGeneral disorders2/293
Subdural haematomaInjury, poisoning and procedural complications1/293
Transfusion reactionInjury, poisoning and procedural complications1/293
Breast cancer recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/293
Gastrointestinal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/293
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/293
Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders1/293
Pleural effusionRespiratory, thoracic and mediastinal disorders1/293
Respiratory failureRespiratory, thoracic and mediastinal disorders1/293

Baseline characteristics

Intention-to-treat (ITT) population consisted of all enrolled participants. Baseline characteristics were collected and reported together for each disease and dose groups (Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 400 mg or 600 mg, Lymphoid Blast Crisis 400 mg or 600 mg, Acute Lymphoblastic Leukemia 400 mg or 600 mg, and Acute Myeloid/Myelogenous Leukemia 600 mg) of participants, as pre-specified in the protocol.

Age, Continuous
Age, Continuous(years)STI571
Mean54.3 ± 12.84
Sex: Female, Male
Sex: Female, Male(Participants)STI571
Female146
Male147
08

Study locations

12 sites
  • Dana Faber Cancer Institute
    Boston, Massachusetts 02115, United States
  • New York Presbyterian Hospital
    New York, New York 10021, United States
  • Oregon Health & Sciences University
    Portland, Oregon 97239, United States
  • MD Anderson Cancer Center, University of Texas
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Pessac, France
  • Novartis Investigative Site
    Poitiers, France
  • Novartis Investigative Site
    Frankfurt, Germany
  • Novartis Investigative Site
    Leipzig, Germany
  • Novartis Investigative Site
    Mainz, Germany
  • Novartis Investigative Site
    Mannheim, Germany
  • Novartis Investigative Site
    Monza, Italy
  • Novartis Investigative Site
    London, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 1999 to primary completion in Sep 2013, 169 months.

Results were first posted in Jul 2021, 7 years 9 months after primary completion.

Of 227 phase 2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 120. This study's 169 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 15, 2005
StartActual
Aug 9, 1999
Primary completionActual
Sep 23, 2013
CompletionActual
Sep 23, 2013
Results first posted
Jul 22, 2021
Last update
Jul 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00171249
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
Aug 9, 1999
Primary completion
Sep 23, 2013
Completion
Sep 23, 2013
Results posted
Jul 22, 2021
Last update
Jul 22, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion